Mckesson's Suppliers recorded an increase in sales by 33.17 % year on year in Q1 2026, sequentially sales grew by 26.49 %, Mckesson recorded an increase in cost of sales by 7.56 % year on year, sequentially cost of sales grew by 10.24 % in Q1.
Mckesson's Suppliers recorded an increase in sales by 33.17 % year on year in Q1 2026, sequentially sales grew by 26.49 %, Mckesson recorded increase in cost of sales by 7.56 % year on year, sequentially cost of sales grew by 10.24 % in Q1.
We obtain pharmaceutical and other products from manufacturers, none of which
accounted for more than approximately 6% of our purchases. The loss of a supplier
could adversely affect our business if alternate sources of supply are unavailable.
We believe that our relationships with our suppliers, on the whole, are good.
The ten largest suppliers accounted for approximately 46% of our purchases.
A significant portion of our distribution arrangements with the manufacturers
provides us compensation based on a percentage of our purchases. In addition,
we have certain distribution arrangements with pharmaceutical manufacturers
that include an inflation-based compensation component whereby we benefit when
the manufacturers increase their prices as we sell our existing inventory at
the new higher prices. For these manufacturers, a reduction in the frequency
and magnitude of price increases, as well as restrictions in the amount of inventory
available to us, could have a material adverse impact on our gross profit margin.
Mckesson's Comment on Supply Chain
We obtain pharmaceutical and other products from manufacturers, none of which
accounted for more than approximately 6% of our purchases. The loss of a supplier
could adversely affect our business if alternate sources of supply are unavailable.
We believe that our relationships with our suppliers, on the whole, are good.
The ten largest suppliers accounted for approximately 46% of our purchases.
A significant portion of our distribution arrangements with the manufacturers
provides us compensation based on a percentage of our purchases. In addition,
we have certain distribution arrangements with pharmaceutical manufacturers
that include an inflation-based compensation component whereby we benefit when
the manufacturers increase their prices as we sell our existing inventory at
the new higher prices. For these manufacturers, a reduction in the frequency
and magnitude of price increases, as well as restrictions in the amount of inventory
available to us, could have a material adverse impact on our gross profit margin.
MCK's Suppliers Net Income grew by
MCK's Suppliers Net margin grew in Q1 to
35.13 %
11.63 %
MCK's Suppliers Net Income grew by 35.13 %
MCK's Suppliers Net margin grew in Q1 to 11.63 %
Mckesson's Suppliers Sales Growth
in Q1 2026 by Industry
Sources:
Mckesson Corporation's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Mckesson Corporation’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
29.42 %